Asthma continues to be a complex respiratory disease to control for many despite optimal standard
inhaler therapy. The increased dependence on
steroid-sparing
biologic treatments in the 21st century has created a dilemma between identifying the patient's intrinsic
biomarkers and their "life markers." With
Tezepelumab being the most recent FDA-approved
biologic for
asthma, it is even more critical for
asthma specialists to better understand and establish a framework to determine which
biologic would work best for their patients. While cost and payor approvals limit access to certain
asthma biologics, medical decisions on which
biologic to select should be centered around shared decision-making, the rationale for
biologic initiation, and critical
biologic education to help achieve successful
asthma control.